Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Medicare will continue to negotiate drug prices in 2025. (HealthDay News) — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 ... nearly doubled since they hit the market and collectively cost Medicare ‒ and American taxpayers ‒ nearly $50 billion ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes and potentially other FDA-approved uses could increase the cost to ...

The high cost of GLP-1 drugs is also putting a strain on Medicare, which spent $4.6 billion on Ozempic for enrollees with diabetes in 2022, prior to discounts and rebates, according to KFF.